Oncology Peer Review On-The-Go: Amy Comander, MD, on SABCS Highlights and Key Breast Cancer Updates from 2021

Podcast

In this episode of "Oncology Peer Review On-The-Go," Amy Comander, MD, spoke with CancerNetwork regarding important developments in breast cancer that took place in 2021 and key clinical trials that read out throughout the year.

After closing the book on the year 2021, CancerNetwork® spoke with Amy Comander, MD, co-medical director and director of breast oncology and cancer survivorship at Mass General Cancer Center, about some of the key developments and data to emerge throughout the year for patients with breast cancer. In particular, she homes in on studies featured at the 2021 San Antonio Breast Cancer Symposium (SABCS).

Not only did Comander detail important information that read out in 2021 for the breast cancer space, but she also touched on how the field is continuously evolving and shared her thoughts on what’s in store for patients in 2022.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.